cyclophosphamide + doxorubicin + fluorouracil + vindesine

This is a combination chemotherapy regimen consisting of four cytotoxic agents: cyclophosphamide, doxorubicin, fluorouracil (5-fluorouracil), and vindesine. Each drug has a distinct mechanism of action targeting rapidly dividing cancer cells: - Cyclophosphamide is an alkylating agent that induces DNA cross-linking, leading to inhibition of DNA replication and cell death. - Doxorubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, disrupting DNA replication and transcription. - Fluorouracil (5-FU) is an antimetabolite that inhibits thymidylate synthase, thereby blocking the synthesis of thymidine required for DNA replication. - Vindesine is a vinca alkaloid that binds to tubulin and inhibits microtubule assembly, arresting cells in metaphase during mitosis. This combination may be used in the treatment of various malignancies where multi-agent chemotherapy regimens are indicated. The specific use of this exact four-drug combination appears rare compared to more established regimens such as CHOP or VDC/IE; however, each component has well-established roles in oncology[2][3][4].